These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
867 related articles for article (PubMed ID: 26597732)
41. Safety and efficacy of sugammadex for the reversal of rocuronium-induced neuromuscular blockade in cardiac patients undergoing noncardiac surgery. Dahl V; Pendeville PE; Hollmann MW; Heier T; Abels EA; Blobner M Eur J Anaesthesiol; 2009 Oct; 26(10):874-84. PubMed ID: 19455040 [TBL] [Abstract][Full Text] [Related]
42. Reversal of neuromuscular blockade by sugammadex after continuous infusion of rocuronium in patients randomized to sevoflurane or propofol maintenance anesthesia. Rex C; Wagner S; Spies C; Scholz J; Rietbergen H; Heeringa M; Wulf H Anesthesiology; 2009 Jul; 111(1):30-5. PubMed ID: 19512873 [TBL] [Abstract][Full Text] [Related]
43. A randomized, dose-finding, phase II study of the selective relaxant binding drug, Sugammadex, capable of safely reversing profound rocuronium-induced neuromuscular block. Groudine SB; Soto R; Lien C; Drover D; Roberts K Anesth Analg; 2007 Mar; 104(3):555-62. PubMed ID: 17312208 [TBL] [Abstract][Full Text] [Related]
44. Reversal of neuromuscular block with sugammadex: a comparison of the corrugator supercilii and adductor pollicis muscles in a randomized dose-response study. Yamamoto S; Yamamoto Y; Kitajima O; Maeda T; Suzuki T Acta Anaesthesiol Scand; 2015 Aug; 59(7):892-901. PubMed ID: 25962400 [TBL] [Abstract][Full Text] [Related]
45. Reversal of rocuronium-induced neuromuscular block with sugammadex in heart failure patients: a prospective observational study. Cammu G; Coart D; De Graeve K; Beelen R Acta Anaesthesiol Belg; 2012; 63(2):69-73. PubMed ID: 23136807 [TBL] [Abstract][Full Text] [Related]
46. Sugammadex and neostigmine dose-finding study for reversal of residual neuromuscular block at a train-of-four ratio of 0.2 (SUNDRO20)†, Kaufhold N; Schaller SJ; Stäuble CG; Baumüller E; Ulm K; Blobner M; Fink H Br J Anaesth; 2016 Feb; 116(2):233-40. PubMed ID: 26787792 [TBL] [Abstract][Full Text] [Related]
47. Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent. Suy K; Morias K; Cammu G; Hans P; van Duijnhoven WG; Heeringa M; Demeyer I Anesthesiology; 2007 Feb; 106(2):283-8. PubMed ID: 17264722 [TBL] [Abstract][Full Text] [Related]
48. Efficacy, safety and pharmacokinetics of sugammadex 4 mg kg-1 for reversal of deep neuromuscular blockade in patients with severe renal impairment. Panhuizen IF; Gold SJ; Buerkle C; Snoeck MM; Harper NJ; Kaspers MJ; van den Heuvel MW; Hollmann MW Br J Anaesth; 2015 May; 114(5):777-84. PubMed ID: 25829395 [TBL] [Abstract][Full Text] [Related]
49. Optimal anesthetic regimen for ambulatory laser microlaryngeal surgery. Huh H; Park SJ; Lim HH; Jung KY; Baek SK; Yoon SZ; Lee HW; Lim HJ; Cho JE Laryngoscope; 2017 May; 127(5):1135-1139. PubMed ID: 27796041 [TBL] [Abstract][Full Text] [Related]
50. Low-Dose or High-Dose Rocuronium Reversed with Neostigmine or Sugammadex for Cesarean Delivery Anesthesia: A Randomized Controlled Noninferiority Trial of Time to Tracheal Intubation and Extubation. Stourac P; Adamus M; Seidlova D; Pavlik T; Janku P; Krikava I; Mrozek Z; Prochazka M; Klucka J; Stoudek R; Bartikova I; Kosinova M; Harazim H; Robotkova H; Hejduk K; Hodicka Z; Kirchnerova M; Francakova J; Obare Pyszkova L; Hlozkova J; Sevcik P Anesth Analg; 2016 May; 122(5):1536-45. PubMed ID: 26974018 [TBL] [Abstract][Full Text] [Related]
51. Half dose sugammadex combined with neostigmine is non-inferior to full dose sugammadex for reversal of rocuronium-induced deep neuromuscular blockade: a cost-saving strategy. Aouad MT; Alfahel WS; Kaddoum RN; Siddik-Sayyid SM BMC Anesthesiol; 2017 Apr; 17(1):57. PubMed ID: 28399799 [TBL] [Abstract][Full Text] [Related]
52. Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade. Abrishami A; Ho J; Wong J; Yin L; Chung F Cochrane Database Syst Rev; 2009 Oct; (4):CD007362. PubMed ID: 19821409 [TBL] [Abstract][Full Text] [Related]
53. Sugammadex: a review of its use in anaesthetic practice. Yang LP; Keam SJ Drugs; 2009; 69(7):919-42. PubMed ID: 19441874 [TBL] [Abstract][Full Text] [Related]
54. The influence of mild hypothermia on reversal of rocuronium-induced deep neuromuscular block with sugammadex. Lee HJ; Kim KS; Jeong JS; Kim KN; Lee BC BMC Anesthesiol; 2015 Jan; 15():7. PubMed ID: 25971394 [TBL] [Abstract][Full Text] [Related]
55. A case series of re-establishment of neuromuscular block with rocuronium after sugammadex reversal. Iwasaki H; Sasakawa T; Takahoko K; Takagi S; Nakatsuka H; Suzuki T; Iwasaki H J Anesth; 2016 Jun; 30(3):534-7. PubMed ID: 26951159 [TBL] [Abstract][Full Text] [Related]
56. Reversal of profound rocuronium neuromuscular blockade by sugammadex in anesthetized rhesus monkeys. de Boer HD; van Egmond J; van de Pol F; Bom A; Booij LH Anesthesiology; 2006 Apr; 104(4):718-23. PubMed ID: 16571967 [TBL] [Abstract][Full Text] [Related]
57. Method for Prediction of Efficacy of Sugammadex Administered to Recover from Rocuronium-Induced Neuromuscular Blockade in Gynecological Laparoscopic Surgery Cases. Kimura K; Omura K; Hoshino T; Takahashi H; Imaura M; Yamada Y Biol Pharm Bull; 2018; 41(3):312-318. PubMed ID: 29491207 [TBL] [Abstract][Full Text] [Related]
58. Sugammadex: the first selective binding reversal agent for neuromuscular block. Kovac AL J Clin Anesth; 2009 Sep; 21(6):444-53. PubMed ID: 19833281 [TBL] [Abstract][Full Text] [Related]
60. Actual versus ideal body weight dosing of sugammadex in morbidly obese patients offers faster reversal of rocuronium- or vecuronium-induced deep or moderate neuromuscular block: a randomized clinical trial. Horrow JC; Li W; Blobner M; Lombard J; Speek M; DeAngelis M; Herring WJ BMC Anesthesiol; 2021 Feb; 21(1):62. PubMed ID: 33639839 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]